Search results
Horizon Therapeutics is a biotechnology company that is driven to deliver breakthrough medicines to patients because we understand the challenges they face.
- 116.30Add to watchlist0.00 (0.00%)As of Tue. Jun 4, 2024 4:00 PM EDT · Delayed Quote (USD) · Market open
- Open116.34High116.30Low116.30
- Mkt CapN/AP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close116.3052 Wk. Low116.3052 Wk. High116.30
Related stocks
Horizon Therapeutics was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. [4]
Oct 6, 2023 · Strengthening of Amgen 's leading inflammation portfolio by adding first-in-class, early-in-lifecycle medicines such as TEPEZZA® (teprotumumab-trbw), KRYSTEXXA® (pegloticase) and UPLIZNA® (inebilizumab-cdon), which treat rare inflammatory diseases.
Dec 12, 2022 · Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, in a deal valued at approximately $26.4 billion.
Mar 1, 2023 · Fourth-quarter 2022 and 2021 adjusted EBITDA includes $37.3 million and $39.7 million, respectively, in acquired in-process research and development (IPR&D) and milestones expenses. Full-year 2022...
Apr 13, 2023 · How Horizon Therapeutics sold to Amgen for $27.8 billion without ever licensing a drug of its own. Horizon Therapeutics CEO Tim Walbert’s company has been particularly adept at ensuring...
Mar 7, 2022 · Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) granted priority review of the supplemental B.
Jun 22, 2023 · DUBLIN, June 22, 2023--Horizon Therapeutics has announced positive topline results from the OPTIC-J clinical trial of TEPEZZA in Japan for active Thyroid Eye Disease (TED).
Feb 1, 2021 · Horizon Therapeutics plc (Nasdaq: HZNP) and Viela Bio, Inc. (Nasdaq: VIE) today announced the companies have entered into a definitive agreement under.
Nov 30, 2022 · Horizon Therapeutics revealed that it's in preliminary discussions about being acquired. Amgen, Johnson & Johnson, and Sanofi have until Jan. 10, 2023, to make offers.
